Le Lézard
Classified in: Health

Samsung Bioepis Announces Health Canada Approval of Citrate-Free High-Concentration of HUMIRA®¹ Biosimilar (adalimumab; SB5)

INCHEON, Korea, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that Health Canada has approved HADLIMAtm (also known as SB5) - a citrate-free, high concentration (40 mg/0.4 ML) formulation of biosimilar referencing HUMIRA® (adalimumab). HADLIMA is indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, ankylosing spondylitis (AS), psoriatic arthritis, adult Crohn's disease, ulcerative colitis, adult and adolescent hidradenitis suppurativa, plaque psoriasis, adult and pediatric uveitis.

"We are pleased to receive Health Canada approval of our high concentration adalimumab biosimilar, marking a key milestone for us now to have both a low and high concentration adalimumab biosimilar approved in Canada," said Byoungin Jung, Vice President and Regulatory Affairs Team Leader at Samsung Bioepis. "The latest approval reflects our continuous efforts to meet the needs of our patients and bring more treatment options available."

The Health Canada approval of the new formulation was based on the result of Phase 1 clinical trial comparing pharmacokinetic (PK), safety, and tolerability of the new SB5 formulation (40 mg/0.4 mL) with prior SB5 formulation (40 mg/0.8 mL) in healthy male subjects. The study demonstrated PK equivalence between new SB5 formulation and prior SB5 formulation in healthy subjects. Both formulations of SB5 were generally well tolerated with similar safety profiles.

HADLIMA was previously approved by Health Canada as a low-concentration (40mg/0.8mL) formulation in May 2018. In Canada, the low-concentration formulation was launched in February 2021 in partnership with Organon. The citrate-free, high-concentration HADLIMA will also be commercialized by Organon, later in 2023.

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology and gastroenterology. For more information, please visit: www.samsungbioepis.com and follow us on social media ? Twitter, LinkedIn.

1 HUMIRA® is a registered trademark of AbbVie

These press releases may also interest you

at 12:05
New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.'s PATHOMIQ_PRAD AI test to assess the risk for metastasis in non-metastatic castration-resistant prostate cancer...

at 12:00
The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the "Active Pharmaceutical Ingredients and High Potency API...

at 12:00
OpenBench, Inc., a pioneer in success-driven small molecule discovery collaborations, today announced the launch of a collaboration with Related Sciences ("RS"), a data science-driven drug discovery studio, to leverage OpenBench's structure-based...

at 12:00
MedVanta, the nation's largest physician-owned and led musculoskeletal management services organization (MSO), today announced the appointment of its first Chief Information Officer, Tony Yi, as well as Christine DeAngelis, Senior Vice President,...

at 12:00
Body-obsessed individuals are being overwhelmed by images of Kardashian glutes and top influencers' magic fat-burning posts. The Internet and social media posts are ripe with the promise of quick weight loss by injecting Semaglutide. The global surge...

at 12:00
A news report from Daily Mail Pakistan: In the fight against the COVID-19 pandemic, one healthcare expert has emerged as a leading authority: Dr.Umar Saeed. With an impressive academic background and extensive experience in infectious diseases,...

News published on and distributed by: